Catheter Cryoablation Versus Antiarrhythmic Drug as First-Line Therapy of Paroxysmal Atrial Fibrillation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 220 participants.
Also called NCT01803438
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 220 participants
- Registry
-
NCT01803438
-
- Other papers using this trial's data
- Initial rhythm control with cryoballoon ablation vs drug therapy: Impact on quality of life and symptoms
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Argentina, Australia, Belgium, Croatia, France, Germany, Italy, Netherlands, Norway
- Registry status
- Completed
Technical summary
Registry record NCT01803438. Randomized; no masking; primary purpose treatment. Start 2014-06 (registry gives no type); primary completion 2019-10-16 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Catheter Cryoablation Versus Antiarrhythmic Drug as First-Line Therapy of Paroxysmal Atrial Fibrillation
- Condition
- Symptomatic Paroxysmal Atrial Fibrillation Without Clinically Significant Heart Diseases
- Intervention (Device)
- cryoballoon ablation system
- Intervention (Drug)
- Antiarrhythmic Drugs
- Lead sponsor
- Medtronic Cardiac Ablation Solutions
Record details
- Record id
cardio:ct-nct01803438- Content hash
b3fa4bce45a4ed0b120939735688dc4e20d09ab6ddb4e387d9ea5bd6b375b397